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Answers to Reviewer #2 
We acknowledge the revision of our manuscript and the comments made by the 
Reviewer.  
 
R#2: The chart and its caption should be put together. 
 
A: According to the Guide for Authors of the Journal, Figure captions have to be 
supplied separately, not attached to the figure.  
 
R#2: Which experiment can explain the sentence 'In addition, chitosan gels with 
complexes resisted better the degradation in simulated vaginal fluid in comparison to 
commercial gel (Crinone®)' in ABSTRACT? 
 
A: Stability experiment showed that after 30 minutes of immersion in simulated vaginal 
fluid, the commercial gel was completely dissolved; while the chitosan gel with 
inclusion complexes showed greater resistance to degradation at the same time. Please 
note that the procedure of the stability experiment was mentioned in Subsection 2.6 
(Lines 214-217) and the results were discussed in Subsection 3.4 (Lines 404-409) of the 
original version of the manuscript. Please also check Figure S2 in Supplementary 
material.  
 
R#2: Why the amount of accumulated PGT in IC solution in 75 hour is less than the 
amount in 60 hour? The same is true for Crinone® and CHT gel+IC. 
 
A: This is an interesting point, thank you for notice it. As you mentioned, this event is 
evident for independent assays, that’s means all release experiments from Figure 8 B 
showed a decrease in accumulated progesterone between 60 and 100 h followed by a 
new step of progesterone release characterized by a different release rate. As this 
behaviour is formulation independent, we could postulate that is a membrane effect. In 
addition, an excess of drug should be applied to the surface of the tissue (infinite dose) 
to guarantee a negligible depletion. In contrast, when a finite dose of drug is applied, the 
relationship between the amount of drug permeated and time is not linear. The 
permeation rate decreases along time. In vitro release studies through porcine epithelial 
mucosa obtained from vaginal tissue were performed on Franz diffusion cells to 
evaluate the release of progesterone from the chitosan gel in comparison with the 
commercial product (Crinone
®
). Despite the mentioned event, the release of 
progesterone and its permeation through the tissue was observed. The profiles of the 
chitosan gel and Crinone
® 
were equivalent.  
 
R#2: What is the advantage of your preparation compared to commercial gel 
(Crinone®)? 
 
A: The chitosan solution and the β-glycerophosphate disodium salt (GP) solution were 
mixed to obtain the gel forming mixture. The incorporation of the inclusion complexes 
(progesterone/cyclodextrin) into the GP solution did not affect the formation of the gel. 
In the commercial product the direct incorporation of the hydrophobic hormone leads to 
the formation of drug crystals even with the presence of oil components in the 
formulation. The chitosan gel was formed in situ and presented a similar in vitro release 
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profile than Crinone
®
. The chitosan gel showed to be superior in respect to the 
simplicity of its preparation. In addition, the ability of chitosan to interact with mucus 
indicates that the residence time of the gel at the vaginal site would be enough to 
provide localized sustained release of progesterone. This information was discussed in 
Subsection 3.5 (Lines 467-475) of the original version of the manuscript. However, 
more information regarding advantages of a chitosan gel for vaginal application was 
added in the revised version to reinforce the presentation of the results (Subsection 3.5, 
Lines 475-484). 
 
R#2: Why is the release time 170 h? If the preparation is needed in the vagina for 170 
hours, will it affect the life quality of the patient? 
 
A: The in vitro release experiments were performed up to 170 h due to this time ensures 
that almost all the progesterone (89 %) in the inclusion complexes solution had 
permeated through the vaginal tissue. For progesterone solution, 100 % of the initial 
amount of hormone permeated at 60 h. The gels presented a diffusion rate lower than 
both progesterone and inclusion complexes solutions, because of the presence of the 
polymeric matrix. The release time (170 h) is not related with the residence time of the 
preparation at the site of application. In vivo release is expected to be faster than in vitro 
performance. This is related with the fact that in the in vitro experiment temperature, 
agitation and the simulated vaginal fluid are used to emulate the vaginal environment. 
Many types of bacteria and other microorganisms are present in a healthy vagina. In 
addition, lysozyme which degrades chitosan can be found. All this components, not 
present in the in vitro experiments, will contribute to the in vivo degradation of the 
chitosan gel and to the release of the hormone.   
 
R#2: Will the drug be completely released from the formulation?    
 
A: We assume that a complete release of progesterone will occur. As was mentioned 
above, in the in vitro experiment conditions to emulate the vaginal environment were 
used. Many types of bacteria and other microorganisms, and enzymes are present in a 
healthy vagina. All this components, not present in the in vitro experiments, will 
contribute to the in vivo degradation of the chitosan gel and to the release of the 
hormone.   
 
 
Answers to Reviewer #3 
We thank Reviewer #3 for his meticulous revision of our manuscript and helpful 
suggestions, which contributed to improve the presentation.  
 
R#3: The introductory plan is not effective, so can be given information about the 
necessity of this formulation in vaginal administration rather than model material. 
Information and examples of vaginal use of chitosan gel should be given: Tuğcu- 
Demiröz F., Acartürk F., Erdoğan D., Development of long-acting bioadhesive vaginal 
gels of oxybutynin: Formulation, in vitro and in vivo evaluations. Int J Pharm. 457 (1): 
25-39, 2013. Tuğcu-Demiröz F., Acartürk F., Özkul A., Preparation and 
Characterization of Bioadhesive Controlled-Release Gels of Cidofovir for Vaginal 
Delivery. J Biomater Sci Polym Ed. 26 (17): 1237-55, 2015. 
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A: The Introduction section is structure in 5 paragraphs. Paragraphs 1 and 2, presents 
progesterone, its application in human health by using different formulations and routes 
of administration with advantages and drawbacks. Paragraph 3, mentions the 
characteristics of the commercial product Crinone
®
.  Paragraph 4, discusses the problem 
of low aqueous solubility of progesterone and how it can be solved by the preparation of 
inclusion complexes with cyclodextrins. Paragraph 5, concludes the Introduction by 
mentioning the objective of the research. We think that this structure is effective. 
Nevertheless, following the Reviewer suggestion, we added information about vaginal 
application of chitosan gels in the revised version (Lines 80-94). New references about 
this topic were included and are marked in red in the References section.  
 
R#3: Your title and content are incompatible. There is no thermosensitive system in 
your study. 
 
A: Chitosan, a cationic amino polysaccharide, combined with β-glycerophosphate 
disodium is an outstanding in situ gel-forming system, which was first reported by 
Chenite et al. (Chenite A et al., Novel injectable neutral solutions of chitosan form 
biodegradable gels in situ. Biomaterials 2000; 21: 2155–2161). This system is available 
at a physiologically acceptable pH and is liquid at room temperature. When the 
temperature is raised to 37 °C, the physiological temperature, it transforms into a gel. 
Chitosan and its derivatives have been used to prepare in situ gel-forming systems (a. 
Ahmadi F et al., Chitosan based hydrogels: characteristics and pharmaceutical 
applications. Res Pharm Sci 2015; 10: 1–16. b. Liu X et al., A novel thermo-sensitive 
hydrogel based on thiolated chitosan/hydroxyapatite/beta-glycerophosphate. Carbohyd 
Polym 2014; 110: 62–69. c. Supper S et al., Thermosensitive chitosan 
/glycerophosphate-based hydrogel and its derivatives in pharmaceutical and biomedical 
applications. Expert Opin Drug Deliv 2014; 11: 249–267. d. Zhou H et al., Design and 
evaluation of chitosan-b-cyclodextrin based thermosensitive hydrogel. Biochem Eng J 
2016; 111: 100–107). The thermosensitive system based on chitosan and β-
glycerophosphate disodium salt used in the present contribution was characterized and 
reported in a previous manuscript published by some of the authors (Mengatto LN et al., 
Application of simultaneous multiple response optimization in the preparation of 
thermosensitive chitosan/ glycerophosphate hydrogels. Iran Polym J 2016; 25: 897–
906). In that work, the information referring to ability of the solution to form the gel, 
temperature and time for sol/gel transition was studied. An optimization process based 
on response surface methodology was carried out in order to develop statistical models 
that describe the relationship between parameters affecting the sol/gel transition and 
final properties of the gel. These equations can be used to prepare gel-forming solutions 
with desired pH, gelling time and residual mass, intended for controlled drug delivery. 
 
R#3: Line 76-82: the aim of the study should be explained in detail and clearly. 
 
A: According to the Reviewer suggestion, we rewrote the aim to render it more clear 
(Lines 90-95). 
 
R#3: Line 89: information on chitosan MW and degree of deacetylation should be 
indicated because these values have an effect on the formulation as in the given 
references: Tuğcu-Demiröz F., Acartürk F., Erdoğan D., Development of long-acting 
bioadhesive vaginal gels of oxybutynin: Formulation, in vitro and in vivo evaluations. 
Int J Pharm 457 (1): 25-39, 2013. Tuğcu-Demiröz F., Acartürk F., Özkul A., 
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Preparation and Characterization of Bioadhesive Controlled-Release Gels of Cidofovir 
for Vaginal Delivery. J Biomater Sci Polym Ed. 26 (17): 1237-55, 2015. 
 
A: We agree with the Reviewer that MW and DD can influence some final properties of 
formulations based on chitosan. The study of these influences in the chitosan 
formulation developed was not the aim of this work. We have expertise in the field of 
chitosan based formulations and we use a chitosan pharmaceutical degree for the 
preparation of our systems. Following the Reviewer suggestion, the information 
concerning to MW and DD was added in the revised version of the manuscript (Lines 
102-103).  
 
R#3: Line 102: Describe in more detail the method you use to analyze progesterone 
with hplc. Is the current method in simulated vaginal fluid? 
 
A: According to these authors, the HPLC methodology is explained in detail. We gave 
information about equipment, column, oven temperature, mobile phase composition, 
flow rate, wavelength of detection and procedure for the preparation of standard 
solutions to obtain the calibration curve. The solvent used for the preparation of 
standard solutions and samples was clarified in the revised version to answer the 
specific question made by the Reviewer (Lines 124-127). 
 
R#3: Line 114: explain why the solubility study was done and why water and ethanol-
water were chosen. 
 
A: Please note that in the subsection 3.1 Phase solubility studies, we explained the aim 
of this study and the information obtained from them. This study describes how the 
increase in cyclodextrin concentration influences drug solubility and are a good starting 
point to increase knowledge about the interaction between the cyclodextrin and the 
drug. From this study a researcher can obtain information about the solubility of the 
complex and the value of the Apparent Stability Constant which indicates the affinity 
between the reactants. For the preparation of the complexes, using the freeze-drying 
method, different solvents can be used: water, buffer, organic solvents or a mixture of 
them. The reason of our choices is: -Water: is the most widely used. -Water:ethanol:  
according to published works on the subject cosolvents, such as ethanol, can enhance 
the solubility of hydrophobic drugs and this will lead to enhanced the complexation 
efficiency (Loftsson, T., Brewster, M.E., 2012. Cyclodextrins as functional excipients: 
methods to enhance complexation efficiency. J. Pharm. Sci. 101, 3019-3032). Different 
proportion of water:ethanol or other organic solvents could be used but that was not the 
objective of our work.  
 
R#3: Line 133: the device used in freeze-drying and its characteristics should be 
indicated. 
 
A: Following the Reviewer suggestion, the device used in freeze-drying procedure was 
clarified (Lines 153-154).  
 
R#3: Line 186: viscosity, rheological and textural studies on chitosan gel can be added. 
Because these studies give important information for drugs to be applied to the vagina. 
What is the pH of the vaginal formulation that you develop is suitable for vaginal 
application? 
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A: Following the reviewer suggestion, viscosity and rheological studies were carried 
out (Lines 218-228). Results are presented in Lines 410-432 of the revised version of 
the manuscript. Textural studies were not carried out. According to our expertise and 
knowledge these tests are performed to evaluate the “mouth feel” properties of food, 
creams or pastes. Since this test is intended to reflect the human perception of texture, 
the compression cycles mimic the human bites (Steffe, J.F. 1996. Rheological Methods 
in Food Process Engineering. 2nd Edition, Freeman Press, East Lansing).  As was 
mentioned in the answer to the second comment, we have developed statistical models 
that describe the relationship between parameters affecting the sol/gel transition and 
final properties of the gel. These equations can be used to prepare gel-forming solutions 
with desired pH, gelling time and residual mass, intended for controlled drug delivery 
(Mengatto LN et al., Application of simultaneous multiple response optimization in the 
preparation of thermosensitive chitosan/ glycerophosphate hydrogels. Iran Polym J 
2016; 25: 897–906). Therefore, we can prepare chitosan gels that fulfil the requirement 
concerning the pH for vaginal application.  
 
R#3: What will be the amount of gel to be administered and how much progesterone 
will it carry? Is the dose of progesterone sufficient? Is it compatible with Crinone?  
 
A: Our first attempt was to develop a formulation with the aim to solve problems 
associated with crystal drug administration, poor retention, irritation and other 
undesirable effects at the site of application of actually used commercial products to 
achieve patient compliance. In this course of action, the use of cyclodextrin allowed the 
hormone to be in a soluble state in the formulation and the chitosan gel showed a 
comparable progesterone release to the commercial product. Regarding the irritation 
problems, these effects would be less significant with the chitosan gel due to the 
formulation has fewer inactive ingredients and the biocompatibility of the polymer was 
showed in vaginal formulations based on the lack of toxicity and absence of 
inflammatory reactions. As we discussed in answers to previous comments, 
mucoadhesion of the polymer was also reported. Features concerning amount of gel to 
be administered and dose of progesterone necessary to reach successful in vivo 
performance are the following steps under study. Optimization of these parameters 
involves a complete new study and it is under consideration.    
 
R#3: Line 203: This release study is not in vitro. This study ex-vivo should be regulated 
accordingly. It is unclear how many repeats the release study has taken.  
 
A: We agree with the Reviewer that an assay carried out by using either human or 
animal vaginal tissue could be considered ex vivo. Nevertheless, we called our study in 
vitro based on the difference with those carried out in animals i.e. in vivo.  According to 
the definition of IUPAC, in vitro means: in glass, referring to a study in the laboratory 
usually involving isolated organ, tissue, cell, or biochemical systems (IUPAC. 
Compendium of Chemical Terminology, 2nd ed. (the "Gold Book"). Compiled by A. D. 
McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). Online 
version (2019-) created by S. J. Chalk. ISBN 0-9678550-9-8. 
https://doi.org/10.1351/goldbook). Therefore, we think it is not incorrect to call the 
experiment in vitro.  At the same time, the study was appropriately designed and carried 
out taking into consideration other similar studies cited in the manuscript (Monteiro 
Machado, R., Palmeira-de-Oliveira, A., Gaspar, C., Martinez-de-Oliveira, J., Palmeira-
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de-Oliveira, R., 2015. Studies and methodologies on vaginal drug permeation. Adv. 
Drug Del. Rev. 92, 14-26). Please note that the procedure was carefully described in the 
Subsection 2.7 (Lines 231-249).  In addition, we mentioned that each assay was 
performed in triplicate (Line 249-249). 
 
R#3: Using too many acronyms is confusing.  
 
A: To render the text less confusing, the following acronyms were replaced: IVF, DS, 
MP, PSD, PM, FTIR, DSC, DLS, SEM and H-NMR.     
 
 
R#3: Figure titles should be more detailed and informative, especially not enough figure 
7. 
 
A: According to the Reviewer suggestion, Figure captions were rewritten to render 
them more detailed and informative.   
 
R#3: Is the study aimed at controlled release? 175 hours, 7 days can also stay in the 
vagina? You need to test it. What is the residence time of this gel in the vagina? 
 
A: The in vitro release experiments were performed up to 170 h due to this time ensures 
that almost all the progesterone (89 %) in the inclusion complexes solution had 
permeated through the vaginal tissue. For progesterone solution, 100 % of the initial 
amount of hormone permeated at 60 h. The gels presented a diffusion rate lower than 
both progesterone and inclusion complexes solutions, because of the presence of the 
polymeric matrix. The release time (170 h) is not related with the residence time of the 
preparation at the site of application. In vivo release is expected to be faster than in vitro 
performance. This is related with the fact that in the in vitro experiment temperature, 
agitation and the simulated vaginal fluid are used to emulate the vaginal environment.  
Many types of bacteria and other microorganisms are present in a healthy vagina. In 
addition, lysozyme which degrades chitosan can be found. All this components, not 
present in the in vitro experiments, will contribute to the in vivo degradation of the 
formulation and to the release of the hormone. 
Regarding the residence time, a comparison between the stability in simulated vaginal 
fluid of the chitosan gel and the commercial formulation (Lines 404-409 and Figure S2) 
and results from rheological measurements (Lines 423-432) could indicate a greater 
resistance to degradation under simulated in vivo conditions for our formulation. In 
addition, the mucoadhesion properties of chitosan that we discussed in previous 
comments together with the new information introduced about the application of 
chitosan gels as an intravaginal formulation contributes to indicate that the residence 
time of the chitosan gel at the vaginal site would be enough to provide localized 
sustained release of progesterone.  
 
R#3: Crinone is used once a day. Is the formulation you developed sufficient to release 
in 24 hours? 
 
A: The analysis of the percentage of accumulated progesterone (%) as a function of 
time in simulated vaginal conditions, indicated equivalence between the chitosan gel 
and the commercial formulation. This comparison was carried out according to a model 
independent approach utilizing a difference factor (f1) and a similarity factor (f2) 
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introduced by Moore and Flanner (Moore JW, Flanner HH. Mathematical comparison 
of dissolution profiles. Pharm Tech. 1996; 20:64–74). As was mentioned in a previous 
comment, features concerning amount of gel to be administered and dose of 
progesterone necessary to reach successful in vivo performance are the following steps 
under study. Optimization of these parameters involves a complete new study and it is 
under consideration.    
 
R#3: Accumulate instead of cumulative. 
 
A: We do not understand this comment because the word cumulative was not used in 
the manuscript.  
 
R#3: Line 426: chitosan has nothing to do with thermosensitivity. 
 
A: The formulation developed in this work is thermosensitive. Please note the answer to 
the second comment made by the Reviewer.  
 
R#3: Experiments and comments on vaginal application should be added. 
 
A: As was mentioned, in vivo performance of the chitosan gel is the following step 
under study. Based on the information of the successful vaginal application of similar 
chitosan formulations discussed above, we are optimist that our system will fulfil with 
the requirements of the hormone therapy. In addition, vaginal irritation and other 
undesirable effects at the site of application reported for commercial products would be 
less significant with the chitosan gel. Our support for this consideration is the fact that 
the formulation has fewer inactive ingredients and the biocompatibility of the polymer 
was showed in vaginal formulations based on the lack of toxicity and absence of 
inflammatory reactions. These comments were developed in Lines 475-484.  
Progesterone loaded thermosensitive hydrogel for vaginal application: formulation 1 
and in vitro comparison with commercial product 2 
Abstract 3 
Progesterone (PGT) is a natural hormone that stimulates and regulates various important 4 
functions, such as the preparation of the female body for conception and pregnancy. Due to 5 
its low water solubility, it is administered in a micronized form and/or in vehicles with 6 
specific solvents requirements. In order to improve the drug solubility, inclusion complexes 7 
of PGT and β-cyclodextrins were obtained by the freeze-drying method. Two β-8 
cyclodextrins (native and methylated) in two solvents (water and water:ethanol) and 9 
different molar ratio of the reagents were the variables tested for the selection of the best 10 
condition for the preparation of the complexes. The PGT/randomly methylated-β-11 
cyclodextrin complexes were incorporated into chitosan thermosensitive hydrogels, as an 12 
alternative formulation for the vaginal administration of PGT. Neither the micro and 13 
macroscopic characteristics of the gels nor the transition time from solution to gel were 14 
modified after the complexes incorporation. In addition, chitosan gels with complexes 15 
resisted better the degradation in simulated vaginal fluid in comparison to commercial gel 16 
(Crinone
®
). The chitosan gel with inclusion complexes and Crinone
®
 were tested in vitro in 17 
a diffusion assay to evaluate the delivery of the hormone and its diffusion through porcine 18 
epithelial mucosa obtained from vaginal tissue.  Chitosan gel presented sustained diffusion 19 
similar to the exhibited by commercial gel. The use of chitosan gels with inclusion 20 
complexes based on cyclodextrins would be a viable alternative for vaginal administration 21 
of PGT.  22 
Keywords 23 
progesterone; methylated-β-cyclodextrin; inclusion complexes; in vitro diffusion; drug 24 
delivery 25 
1. Introduction 26 
Progesterone (PGT) is a natural steroid hormone involves in the preservation of normal 27 
physiology of female reproductive system. In this way, exogenous PGT is used as 28 
medication in the prevention of preterm birth, in luteal phase support for in vitro 29 
fertilization, in hormone replacement therapy and in endometrial hyperplasia and primary 30 
endometrial carcinoma treatment (Scavone et al., 2016). 31 
PGT can be administered by different routes: oral, intramuscular and vaginal; having many 32 
options for its formulation (Scavone et al., 2016; Almomen et al., 2015; Cometti, 2015). In 33 
general, the current commercially available formulations present advantages and 34 
drawbacks. For example: capsules for oral administration allow achieving low endometrial 35 
concentrations of the drug because of the first pass metabolism by the liver; and 36 
intramuscular injections can cause pain and irritation at the injection site reducing the 37 
patient's compliance and the therapeutic efficacy. The use of vaginal route can cause 38 
vaginal discharge, irritation and mild application site reactions. Nevertheless, it exhibits a 39 
preferential absorption, since the drug is transported directly to the uterus (Almomen et al., 40 
2015; Cometti, 2015; Choudhury et al., 2011; Lockwood et al., 2014). 41 
*Manuscript (WITHOUT Author Information)
Click here to view linked References
Crinone
® 
is a white soft gel commercially available in boxes containing 6, 15 or 18 42 
applicators. The applicator is designed to deliver a pre-measured dose of the gel directly 43 
into the vagina. This gel showed an efficacy comparable to intramuscular formulations, 44 
achieving a stable endometrial PGT concentration with low serum levels, while reducing 45 
adverse systemic effects (Michnova et al., 2017; Silverberg et al., 2012; Moini et al., 2011; 46 
Wang et al., 2015). The carrier vehicle is an oil-in-water emulsion. However, the PGT is 47 
only partially soluble in both phases; the majority of the hormone exists as a suspension in 48 
micronized scale. In addition, its main components are cross-linked acrylic acid polymers 49 
(carbopol and polycarbophil), which accumulate in the tissue generating vaginal irritation, 50 
painful sexual intercourse and other side effects (Check, 2009). 51 
In pharmaceutical technology, the design and development of novel drug delivery systems 52 
aim to increase efficiency of drug delivery and safety in the course of administration and 53 
treatment, providing more convenience for the patient. During the optimization of PGT 54 
formulations, increasing its aqueous solubility is one of the first problems to be overcome. 55 
In some dosage forms, it is necessary the use of oils owing to PGT being practically 56 
insoluble in water (7 mg/L or 22.26 μM, at 25 °C). Cyclodextrins (CDs) are cyclic 57 
oligosaccharides produced by selective enzymatic synthesis from starch.  CDs have a three-58 
dimensional structure with a hydrophobic cavity and a hydrophilic exterior, making them 59 
useful tools to improve the aqueous solubility of insoluble (or lowly soluble) drugs. Since 60 
they are natural products, they have a very low toxic effect and can be used in medicines, 61 
food and cosmetics (Messner et al., 2010; Loftsson and Brewster, 2012). In addition to 62 
natural CDs, chemically modified CDs are extensively used. In general, CDs consist of 6, 7 63 
or 8 glucopyranose units, linked by α-(1-4) bonds, known as α-, β- and γ-CDs, respectively 64 
(Messner et al., 2010; Del Valle, 2004). The hydrophobicity of their internal cavity 65 
provides them the capacity to act as a host and form stable structures, called inclusion 66 
complexes (ICs), with other molecules of very diverse nature (guest). These complexes 67 
exhibit new physicochemical characteristics, since bioavailability, water solubility, stability 68 
in light presence, heat or oxidation conditions of the included drug are improved, at the 69 
same time that unwanted side effects may decrease (Chaudhary and Patel, 2013; Chordiya 70 
and Senthilkumaran, 2012; Sharma and Baldi, 2014). ICs between PGT and natural or 71 
modified CDs have been prepared by different methods such as precipitation, freeze-drying 72 
and spray-drying, providing remarkable improvement in PGT water-solubility (Scavone et 73 
al., 2016; Lahiani-Skiba et al., 2006; Zoppetti et al., 2007 b; Cerchiara et al., 2003; 74 
Lockwood et al., 2014). 75 
With the advent of in vitro fertilization and other assisted reproductive procedures, vaginal 76 
formulations of PGT became again the focus of research and one option to administer PGT 77 
through this route is gels. CHT is a biodegradable and biocompatible linear polymer which 78 
can be used in pharmaceuticals formulations as in situ thermosensitive hydrogels (Mengatto 79 
et al., 2016). In addition, CHT gels have been proposed for vaginal delivery of different 80 
active ingredients. This polymer possesses remarkable features such as good mucoahesion 81 
which improve the retention of the formulation inside the vagina, antimicrobial attributes, 82 
and suitable mechanical, release and penetration enhancer properties (Caramella et al., 83 
2015; Tuğcu-Demiröz et al., 2015; Cook and Brown, 2018). CHT gels developed for the 84 
vaginal delivery of oxybutynin presented the easiest application in comparison to other 85 
formulations and histological studies showed that the drug was absorbed without damaging 86 
the tissue due to the polymer has preventative effect against cell damage (Tuğcu-Demiröz 87 
et al., 2013). Stability and durability studies performed on a CHT based gel for vaginal 88 
application of PGT suggested extended residence time due to mucoadhesion and 89 
thermosensitive properties of the polymer (Almomen et al., 2015). The aim of our work 90 
was the preparation of gels based on CHT and PGT/randomly methylated-β-cyclodextrin 91 
complexes. The CHT gel with ICs and Crinone
®
 commercial product were tested in a 92 
release experiment to compare the delivery of the hormone and its diffusion performance 93 
through porcine epithelial mucosa obtained from vaginal tissue. Therefore, CHT gels 94 
containing ICs were studied as an alternative formulation for vaginal application of PGT. 95 
 96 
2. Materials and methods 97 
2.1 Materials 98 
PGT (MW = 314.45 g/mol, purity 99.2 %) was acquired in Farmabase (Italy). RAMEβ-CD, 99 
(MW = 1291.8 g/mol, Degree of substitution = 12) was purchased from Cyclolab 100 
(Hungary). β-CD (MW = 1135 g/mol) was donated (Roquette, France). Crinone® 8 % gel 101 
(Merck-Serono) was purchased at a local supplier. CHT (MW = 600000 g/mol, Degree of 102 
deacetylation = 75-85 %) was purchased from China Easter Group (China). β-103 
glycerophosphate disodium salt (GP) was kindly provided by Surfactan S.A. (Argentina). 104 
The water was of Milli-Q quality (Millipore, USA). Ethanol (EtOH), acetic acid and lactic 105 
acid were analytical grade (Cicarelli, Argentina). Methanol (MeOH) was HPLC grade 106 
(Merck, Germany). Isotonic phosphate buffer saline with EtOH (PBS-EtOH, 80:20 v:v, pH 107 
= 7) was prepared by mixing 800 mL of PBS with 200 mL of EtOH. PBS was prepared by 108 
dissolving 8 g of NaCl, 0.2 g of KCl, 0.2 g of KH2PO4, 1.44 g of Na2HPO4∙2H2O in 1 L of 109 
water. Simulated vaginal fluid (SVF, pH = 4.2) was prepared by dissolving: 3.51 g NaCl, 110 
1.4 g KOH, 0.222 g Ca(OH)2, 0.018 g of bovine serum albumin, 2 g of lactic acid, 1 g of 111 
acetic acid, 0.16 g of glycerol, 0.4 g of urea and 5 g of glucose in 1 L of water (Marques et 112 
al., 2011). Potassium bromide (KBr) and reagents of PBS and SVF solutions were 113 
analytical grade (Anedra, Argentina).  114 
 115 
2.2 PGT quantification by HPLC 116 
The concentration of PGT was determined by a HPLC system (Prominence Series 20A, 117 
Shimadzu).  The chromatographic separation was performed using a Zorbax Eclipse XDB-118 
C18 column (250 x 4.6 mm, 5 μm pore size) (Agilent). The conditions of analysis were: 119 
oven temperature 30 °C, mobile phase MeOH:water (95:5, v:v), flow rate 1 mL/min and the 120 
wavelength of detection 254 nm (Helbling et al., 2015).  121 
A stock solution of PGT (300 μg/mL) in MeOH was prepared. In order to verify the 122 
linearity of the analytical procedure within a concentration range of 1-100 μg/mL of PGT, 123 
six concentration levels of standard solutions were prepared in mobile phase and analyzed 124 
in triplicate. The calibration curve (Absorbance as a function of PGT concentration) was 125 
fitted to a straight line using linear regression analysis. Experimental samples were diluted 126 
in mobile phase as necessary. 127 
2.3 Phase solubility studies 128 
Phase solubility diagrams were obtained following the methodology developed by Higuchi 129 
and Connors (1965). A fixed amount of PGT (in excess) and increasing amounts of CD (β-130 
CD: 0-2mM or RAMEβ-CD: 0-150mM) were placed in amber glass containers with a 131 
specific solvent (water or water:EtOH 50:50, v:v). The containers were stored at 37 °C with 132 
orbital shaking (100 rpm) for 1 week. Once the equilibrium was reached, the containers 133 
were centrifuged, the supernatants were filtered (0.22 μm) and the concentration of PGT 134 
was measured by HPLC. Each experiment was performed in triplicate.  135 
The linear portion of the solubility diagrams was fitted to a straight line with slope and 136 
intercept. The Apparent 1:1 Stability Constant (K1:1) was calculated according to the 137 
Higuchi-Connors equation (Higuchi and Connors, 1965): 138 
 1 1   
 lope
 o     1 -  lope 
                                             Equation 1 139 
where So is the intrinsic solubility of PGT in the solvent without CD (y-intercept) and Slope 140 
is the slope of the straight line.  141 
In addition, the Complexation Efficiency (CE) was calculated (Equation 2). This parameter 142 
was proposed by Loftsson and Brewster (2012) and relates the concentration of CD that 143 
forms a complex and the concentration of free CD:  144 
CE   
 lope 
 1 -  lope 
                                           Equation 2 145 
2.4 Preparation of PGT/CD inclusion complexes 146 
PGT/RAMEβ-CD ICs were obtained by the freeze-drying method. First, PGT was 147 
dissolved in EtOH and a proportional amount of RAMEβ-CD was dissolved in water 148 
(PGT:RAMEβ-CD molar ratios 1:1; 1:5; 1:10 and 1:20). Both solutions were mixed and 149 
magnetically stirred for 15 min. Then, the containers were placed in an ultrasonic bath for 5 150 
min. The organic solvent was removed under reduced pressure with a rotary evaporator and 151 
the solution was centrifuged to remove reagents that did not form a complex. The 152 
supernatant was frozen at -80 °C and freeze-dried for 24 hs at 1 mbar pressure in a 153 
laboratory freeze dryer (Cryodos -80, Telstar). 154 
In order to evaluate the inclusion procedure, efficacy and yield were calculated.  155 
The mobile phase used for PGT quantification by HPLC contains MeOH, then it can 156 
dissolve the free and the included PGT. In water, only the included PGT will be dissolved 157 
(Bouquet et al., 2007). The same amount of sample was dissolved in water and in mobile 158 
phase and the solutions were analyzed by HPLC.  159 
The Inclusion Efficacy (E%) was calculated according to the following equation: 160 
      
C     
C           
   100                                  Equation 3 161 
where Cwater and CMP are the PGT concentrations in the sample dissolved in water and MP, 162 
respectively. An E% value near 100 % was considered as a successful interaction and/or 163 
formation of complexes between PGT and RAMEβ-CD. 164 
The Inclusion Yield (Y%) was calculated according to the following equation: 165 
      
PGTfinal
PGTini ial
 . 100       Equation 4 166 
where PGTfinal is the mass of PGT recovered at the end of the freeze-dried procedure in the 167 
total lyophilized material and PGTinitial is the initial mass of PGT used to prepare the ICs. 168 
2.5 Characterization of PGT/CD inclusion complexes 169 
Differential scanning calorimetry  170 
Approximately 5 mg of the sample were weighed into aluminum capsules and tested on a 171 
Mettler DSC821e thermal analyzer (Mettler Toledo). All the assays were carried out under 172 
controlled nitrogen atmosphere and with a heating rate of 10 °C/min. The samples were 173 
PGT, RAMEβ-CD, and both the physical mixture and the IC in a 1:1 molar ratio. 174 
 175 
Nuclear magnetic resonance 176 
Nuclear magnetic resonance spectra were obtained using an AVANCE 300 MHz 177 
spectrometer (Bruker). The samples (PGT and the IC in a 1:1 molar ratio) were dissolved in 178 
deuterated chloroform (CDCl3) at 25 °C. A chemical shift (δ) of 7.26 ppm for CDCl3 was 179 
used as internal reference. 180 
The variation of chemical shift (Δδ) of the protons in the PGT due to the inclusion of the 181 
hormone into the cavity of the CD was calculated applying the following equation: 182 
Δδ   δ   δ                   Equation 5 183 
where δIC is the proton shift of the PGT in the IC and δFree is the proton shift of the PGT 184 
when it is free i.e. not included. 185 
 186 
Dynamic light scattering  187 
The hydrodynamic size and size distribution measurements were carried out by dynamic 188 
light scattering using a Zetasizer Nano-ZS (Malvern). A sample of the RAMEβ-CD and the 189 
IC in a 1:5 molar ratio were dissolved in Milli-Q water and placed in a polystyrene cuvette 190 
(dimensions: 1.0 x 1.0 cm). The sample was irradiated with a He-Ne laser (λ   633 nm) at 191 
25 ºC. The refractive index was set at 1.33 and the viscosity at 0.8872 cP. The intensity of 192 
the scattered light was detected with a backscattering angle of 90 °.  193 
 194 
Scanning electron microscopy  195 
Micrographs were obtained by observation with a Phenom ProX Desktop Scanning 196 
Electron Microscopy (Thermo Fisher). The observations were made using an acceleration 197 
voltage of 15.0 kV. The samples were: PGT, RAMEβ-CD, and both the physical mixture 198 
and the IC in a 1:5 molar ratio. 199 
 200 
2.6 CHT gels with inclusion complexes 201 
CHT (2% w/w) was dissolved in an acetic acid solution (0.15 M). GP (35 % w/w) and the 202 
PGT/RAMEβ-CD ICs were dissolved together in water. Both solutions were mixed and 203 
allowed to gel at 37.5 °C (Mengatto et al., 2016).  204 
The gels were characterized by Fourier-transform infrared spectroscopy, scanning electron 205 
microscopy, stability in SVF and rheological measurements. Infrared spectroscopy studies 206 
were performed on a FTIR-8201 PC spectrometer (Shimadzu), in the frequency range of 207 
400-4000 cm
-1
 at a resolution of 8 cm
-1
 and 40 scans per spectrum. A weighed amount of 208 
sample was blended with KBr and compressed to obtain disks. The concentration of each 209 
sample in the disk was approximately 1 % in order to obtain more defined spectra.  210 
Microscopic observations were carried out with a Phenom ProX Desktop Scanning 211 
Electron Microscopy (Thermo Fisher). The samples were frozen and freeze-dried before 212 
observations. 213 
The stability of the CHT gel with ICs and the commercial gel (Crinone
®
) in SVF (pH = 4.2) 214 
was determined. A weighed amount of the gels was placed in baskets-type containers that 215 
were submerged in 20 mL of SVF and were maintained at 37 ºC. At different times the 216 
baskets with the gels were gently removed and weighed. 217 
Rheological measurements were performed on a rheometer (Haake RheoStress RS80, 218 
Haake Instrument Inc.) with parallel plates (35 mm diameter, 2 mm gap). The temperature 219 
of the lower plate was maintained at 37 °C with a circulating bath water. Sand paper in the 220 
upper plate was used to eliminate slippage (Olivares et al., 2012). The linear viscoelastic 221 
region was determined by performing strain sweep tests from 0.01 to 0.1 at 10 Hz. 222 
Frequency sweep tests were performed from 0.1 to 10 Hz at strain amplitude of 0.03 (strain 223 
deformation within the linear viscoelastic region). The dynamic rheological data obtained 224 
included the 2 components of complex shear modulus (G*): the storage modulus (G´) and 225 
the loss modulus (G´´), and the complex viscosity (|η*|   |G*|/ω, ω  frequency of 226 
oscillation). The samples were CHT gel+IC and Crinone
®
 freshly prepared and after 15 min 227 
of immersion in SVF (37 °C). Each experiment was performed in triplicate. 228 
 229 
2.7 In vitro release experiments 230 
Release experiments were performed using a vertical Franz diffusion cell (PermeGear Inc., 231 
USA), with a diffusion area of 1.77 cm
2
 and 12.0 mL of receptor compartment volume. 232 
Porcine vaginal tissue, obtained from females between 5 and 6 months of age, was donated 233 
by a local slaughterhouse (Figan, Santa Fe, Argentina). Immediately after the animals were 234 
sacrificed, the vaginal tissue was removed and placed in PBS until it arrived at the 235 
laboratory. 236 
The epithelial mucosa was carefully separated, fractionated and stored at -80 ºC. The day 237 
before the experiment, a sample of the tissue was thawed and stabilized in buffer solution. 238 
Subsequently, it was placed between both compartments with its luminal face towards the 239 
donor compartment. The delivery systems tested in the donor compartment were: PGT 240 
solution, ICs solution, CHT gel+ICs and commercial gel. The solutions were prepared in 241 
SVF:EtOH 80:20 (v:v). In the case of the gels, 0.25 mL of SVF were placed over them to 242 
mimic the vaginal environment conditions and prevent gel dryness. The donor compartment 243 
was covered to avoid evaporation. The receptor compartment was continuously stirred and 244 
maintained at 37.5 °C. EtOH was used to ensure the solubility of the hormone (Monteiro 245 
Machado et al., 2015). The initial concentration of PGT in the four systems was the same. 246 
 amples of 200 μL were withdrawn at regular intervals of time and replaced with fresh 247 
medium. The amount of PGT was quantified by HPLC. Each assay was performed in 248 
triplicate. 249 
The percentage of accumulated PGT (%) was represented as a function of time (t). 250 
The permeation profiles were compared using the difference (f1) and similarity (f2) factors 251 
(Cascone, 2017). These factors were calculated by the following equations: 252 
  253 
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where n is the number of samples, Rt and Tt are the percentages of drug released from the 257 
reference product and the system to be evaluated, respectively, for each time t. Two profiles 258 
were considered equivalent when the value of f1 is less than 15 and f2 is in the range 50-100 259 
(Cascone, 2017). 260 
 261 
2.8 Statistical analysis 262 
ANOVA and Fisher test were used to compare two or more means, respectively. 263 
 264 
3. Results and discussion 265 
3.1 Phase solubility studies 266 
Solubility diagrams for the β-CD and the RAMEβ-CD are presented in Figure 1 A and B, 267 
respectively. Although the study do not verify the formation of the ICs, they describe how 268 
the drug solubility increases when CD concentration increases (Messner et al., 2010), 269 
providing valuable information about their interaction. Solubility diagrams of the PGT with 270 
β-CD in water (Fig. 1 A) showed a behavior of the Bs type, according to the classification 271 
of Higuchi and Connors (1965). This suggests the formation of complexes of limited 272 
solubility in water (Uekama et al., 1982; Lahiani-Skiba et al., 2006). Solubility diagrams of 273 
the PGT with RAMEβ-CD (Fig. 1 B) presented typical curves of the AL type. The diagrams 274 
showed that the PGT solubility increases linearly with the concentration of RAMEβ-CD 275 
throughout the range of CD concentrations studied, due to the formation of soluble 276 
complexes. Lahiani-Skiba et al. (2006) evaluated the behavior of PGT with a trimethylated 277 
β-CD and Luppi et al. (2005) with a dimethylated β-CD. These authors reported AL type 278 
profiles. The PGT solubility in the absence of RAMEβ-CD (So) was greater in the solution 279 
with EtOH in comparison to water. The addition of an organic cosolvent renders the 280 
mixture more favorable for the dissolution of a hydrophobic solute such as PGT (Loftsson 281 
and Brewster, 2012).  282 
Table 1 shows the values of So (y-intercept), K1:1 and CE, calculated with Equation 1 and 2, 283 
respectively. K1:1 value for the RAMEβ-CD in water indicated a strong affinity of the CD 284 
for the PGT (Luppi et al., 2005; Lahiani-Skiba et al., 2006; Ma et al., 2011). This behavior 285 
is due to the high hydrophobicity of the PGT (partition coefficient in an octanol-water 286 
system: Poct = 7410; Tomida et al., 1978). Also, the K1:1 obtained in water (74526.09 M
-1
) 287 
was higher than that obtained for the mixture water:EtOH (27.13 M
-1
). As the organic 288 
portion of the medium increases, the apparent constant decreases due to a reduction of the 289 
polarity of the medium (Loftsson and Brewster, 2012).   290 
The value of the constant for the β-CD (46256.79 M-1) indicated that the CD is also very 291 
effective in forming stable complexes. The difference in the PGT interaction with natural 292 
CD and its methylated derivative could be explained taking into account the differences in 293 
aqueous solubility (Popielec and Loftsson, 2017). In the RAMEβ-CD, the methyl groups, 294 
increase the hydrophobicity of the cavity and facilitate drug binding (Cirri et al., 2005).  295 
The estimation of K1:1 is affected by the value of the solubility. Therefore, Loftsson and 296 
Brewster (2012) proposed the calculation of CE. This parameter is independent of the 297 
solubility and it is more suitable for the determination of the solubilizing effect of CDs. The 298 
CE values agreed with typical values reported for aqueous media (CEaverage0.3) (Loftsson 299 
and Brewster, 2012). The CE obtained for the CDs in water (β-CD = 0.489 and RAMEβ-300 
CD = 0.433) were slightly higher (p < 0.05) than that obtained for the mixture water:EtOH 301 
(0.362). Therefore, in water, 1 of each 3 CD molecules is assumed to form a water soluble 302 
complex.  For RAMEβ-CD in water:EtOH, 1 of each 4 CD molecules formed a water 303 
soluble complex (Loftsson et al., 2007). Both CDs can form stable complex with PGT. 304 
Nevertheless, RAMEβ-CD was selected for the preparation of the ICs based on its excellent 305 
aqueous solubility and due to the obtained complexes also being soluble. 306 
  307 
3.2 Preparation of PGT/CD inclusion complexes 308 
The preparation of the complexes was carried out using water and water:EtOH (50:50, v:v) 309 
as solvents. Although most of the studies report 1:1 or 1:2 molar ratios (PGT:CD), 310 
experiments with higher ratios were done in order to evaluate their effect on the ICs 311 
formation. Inclusion Efficacy (E%) and Inclusion Yield (Y%) were calculated with 312 
Equations 3 and 4, respectively. In general, these parameters are not reported in the 313 
bibliography; however, they are very useful to evaluate the inclusion method. The ICs 314 
prepared in water presented E% values greater than 90 %, but Y% values were lower than 40 315 
%. For this reason, water:EtOH was the solvent selected for the ICs preparation throughout 316 
the work. 317 
In Table 2, E% and Y% for ICs prepared in water:EtOH are presented. E% was greater than 318 
95 % when RAMEβ-CD concentration increased up to a molar ratio of PGT:RAMEβ-CD 319 
1:10. Any further increase in CD concentration (1:20) decreased E%, probably due to CD 320 
precipitation (Frömming and Szejtli, 1993 a; Frömming and Szejtli, 1993 b). Regarding 321 
Y%, this value was in the range of 77-91 % for molar ratios equal or higher than 1:5. For the 322 
molar ratio 1:1, Y% was the lowest (p < 0.05). When higher CD concentrations are used, the 323 
CD + PGT ↔ IC equilibrium is displaced to the complexes formation. In addition, other 324 
structures between the PGT and the RAMEβ-CD, such as non-inclusion complexes or 325 
aggregates can coexist with the ICs (Shakalisava and Regan, 2006; Loftsson et al., 2007). 326 
Also, there is an increase in variability with an increase in the concentration of CD. The 327 
molar ratio 1:5 was selected for the preparation of ICs for the in vitro release experiments 328 
due to E% and Y% presented the best values with the less CD concentration.  329 
  330 
3.3 Characterization of PGT/CD inclusion complexes 331 
In order to verify the formation of the ICs, thermal analysis, proton nuclear magnetic 332 
resonance, dynamic light scattering and scanning electron microscopy experiments were 333 
carried out. The thermal behavior of PGT, RAMEβ-CD, and both the physical mixture and 334 
the lyophilized IC in a 1:1 molar ratio was studied (Fig. 2). PGT thermogram showed the 335 
characteristic melting peak of the drug at 130.9 °C (Lahiani-Skiba et al., 2006; Zoppetti et 336 
al., 2007 a; Li et al., 2018). In the physical mixture thermogram, a shift of the PGT 337 
endothermic peak to a slightly lower temperature (127.9 °C) was observed. According to 338 
Lahiani-Skiba et al. (2006), the explanation could be the existence of a very weak 339 
interaction at high temperatures between the PGT and the CD. In the IC thermogram, the 340 
absence of the melting peak of the PGT supported the formation of the complex (Lahiani-341 
Skiba et al., 2006; Cerchiara et al., 2003). RAMEβ-CD did not produce any peaks of 342 
interest in the studied temperature range. 343 
The chemical structure with numbering of protons for each molecule is shown in Figure S1. 344 
The nuclear magnetic resonance spectra obtained for the PGT and the IC are presented in 345 
Figure 3. Inner protons of the RAMEβ-CD (H3 and H5), and protons H4, H18, H19 and 346 
H21 of the PGT (Figure S1) are the most affected during inclusion of the drug into the 347 
cavity of the CD (Frömming and Szejtli, 1993 a; Salústio et al., 2009; Zoppetti, 2011). A 348 
well-resolved nuclear magnetic resonance spectrum for the RAMEβ-CD was not obtained, 349 
possibly due to the presence of residual β-CD content. As a result, only some of the signals 350 
could be identified unambiguously. Signals of H3, H5 and H6 produced wide peaks caused 351 
by overlapped signals. For this reason, IC formation between PGT and RAMEβ-CD was 352 
studied only on the basis of the chemical changes of the drug (Jablan et al., 2011; García et 353 
al., 2014).The variation of chemical shift (Δδ) of the protons in the PGT due to the 354 
inclusion was calculated (Table 3). The greatest change was observed in H4, indicating that 355 
A ring may be the part of PGT involved in IC formation (Uekama et al., 1982).  356 
IC and RAMEβ-CD were characterized by dynamic light scattering. Hydrodynamic 357 
diameter based on number (Dn) and polydispersity index (PDI) of the samples were 358 
obtained. One population was observed in the RAMEβ-CD sample, corresponding to 359 
monomeric CD (Dn: 1.1±0.3 nm) with PDI value of 0.567±0.014, which would indicate the 360 
presence of some CDs aggregates. The sample with the complexes also displays one 361 
population (Dn: 142.8±6.8 nm, PDI: 0.199±0.011) that presented a larger size than the 362 
monomeric CD. CDs and ICs can form aggregates, but in most cases they are small 363 
(Loftsson et al., 2007). In our case, the aggregates of the PGT/RAMEβ-CD ICs did not 364 
affect the optical properties of the solutions since they remained transparent. 365 
Electron micrographs of PGT, RAMEβ-CD, physical mixture and IC were obtained (Fig. 366 
4). PGT (A) presented a form of irregular granules and RAMEβ-CD (B) displayed hollow 367 
spherical particles and porous fragments. The physical mixture (C) showed a mixture of 368 
PTG and RAMEβ-CD structures. IC (D) morphology, by contrast, was observed like 369 
plates/plane structures with regular edges. The comparison of the images reveals that the 370 
ICs are structurally distinct from the CD and the physical mixture, which supports the PGT 371 
inclusion into the RAMEβ-CD cavity. 372 
 373 
3.4 CHT gels with inclusion complexes   374 
Figure 5 shows infrared spectra of CHT gel, IC, CHT gel+IC, Crinone
®
 and PGT. CHT 375 
gel+IC spectrum presented the characteristic peaks of their constituent components, with 376 
some variations. The band at 3400 cm
-1
 corresponding to the superposition of the -OH and -377 
NH stretching vibrations shifted towards 3465 cm
-1
. These groups are involved in the 378 
formation of inter and/or intramolecular hydrogen bonds (Islam et al., 2013), therefore the 379 
IC could present this type of interaction with the CHT molecule. The vibration of the -CH 380 
and -CH2 groups of the CD in the region between 2800-3000 cm
-1
 (2920 cm
-1
) and the peak 381 
corresponding to the group -OCH3 (2852 cm
-1
) were observed in the CHT gel+IC spectrum. 382 
The intensity of the band at 1650 cm
-1
 corresponding to C=O stretching vibration in amide 383 
I, changed after the addition of the IC to the gel. Similar changes were present in the peaks 384 
at 1458, 1419 and 1325 cm
−1
 corresponding to –OH and –CH bending and C–O stretching 385 
of the CHT molecule. In addition, there were significant changes in the spectral shape from 386 
900 to 1250 cm
−1
. The intensity of the bands at 1080 and 980 cm
−1
 decreased and a clear 387 
peak appeared at 1222 cm
-1
. The IR spectrum obtained of the PGT agreed with the results 388 
reported by other authors (Zoppetti et al., 2007 b; Lahiani-Skiba et al., 2006; Cerchiara et 389 
al. 2003; Liu et al., 2007; Li et al., 2018). The peaks corresponding to the stretching of the 390 
C-H bond of CH2 and CH3 groups were observed in the region 2950-2850 cm
-1
. The 391 
spectrum also showed the peaks at 1699 and 1662 cm
-1
 of the stretching of the C=O. In 392 
addition, the peak corresponding to the stretching of the C=C bond was noticed at 1614 cm
-393 
1
. Some of the peaks of the PGT appeared in the spectrum of Crinone® which possesses an 394 
overly complex matrix to make thorough analysis by this technique.  395 
CHT gel, CHT gel+IC and Crinone
®
 electron micrographs were obtained (Fig. 6). CHT gel 396 
(A) presented an open structure characterized by interconnected pores (Goycoolea et al., 397 
2011; Ho et al., 2004). On the other hand, the CHT gel+IC (B) presented a microstructure 398 
similar to interconnected sheets with bigger pores. The structure of gels did not present 399 
important changes with the incorporation of the IC; they showed a good macroscopic 400 
consistency and the formation times were not modified in comparison to those of the blank 401 
gel. Crinone
®
 (C) presented a smooth morphology with visible PGT crystals embedded 402 
throughout the material and absence of pores. 403 
In order to study the stability of the CHT gel+IC and commercial gel in an acid medium 404 
(pH = 4.2) similar to in vivo condition, gels were placed in simulated vaginal fluid (SVF) at 405 
37 °C. After 30 minutes, the commercial gel was completely dissolved, while the CHT 406 
gel+IC showed greater resistance to degradation at the same time (Figure S2). Due to the 407 
lack of stability of the commercial gel it was not possible to obtain the variation of the 408 
weight over time. 409 
The value of the strain amplitude was set at 0.03 (3%) after checked that all measurements 410 
were carried out within the linear viscoelastic region, where G* is independent of the strain 411 
amplitude (Figure S3). Figure 7 (A and B) shows typical frequency dependence of the 412 
storage and loss moduli for CHT gel+IC and Crinone
®
 freshly prepared and after 15 min of 413 
immersion into SVF (37 °C). The time of immersion was fixed in 15 min taking into 414 
consideration that during stability study the commercial gel was completely dissolved after 415 
30 min. All samples showed values of G′ higher than G″ without exhibiting crossing point 416 
throughout the frequency range. Both gels can be classified as strong or true gels, because 417 
the molecular rearrangements within the network are reduced over the time scales analyzed 418 
and G′ is almost independent of the frequency (Rao, 1999). Freshly prepared CHT gel+IC 419 
and Crinone
®
 samples show similar viscoelastic characteristics, i.e., the samples presented 420 
similar values of G′ and G″. After the immersion into SVF, some differences in the 421 
viscoelastic characteristics were noted. While the values of the moduli (G′ and G″) of 422 
Crinone
®
 decreased, the values of CHT gel+IC slightly increased. These results suggest 423 
that CHT gel+IC better preserves its structure and its strong gel characteristic after being 424 
exposed to SVF conditions than Crinone
®
. Figure 7 (C and D) presents typical curves of 425 
complex viscosity as function of frequency. This material function determined under 426 
oscillatory shear testing allows the analysis of viscosity behavior of gel-type samples since 427 
it is a test that minimally disturbs the material avoiding the gel fracture. It is observed that 428 
all samples are shear thinning. However, while Crinone
®
 decreased its viscosity and shear 429 
thinning character after the immersion into SVF, the viscosity and shear thinning character 430 
of CHT gel+IC increased. These results may indicate that the CHT gel+IC sample with 431 
higher viscosity may stay longer inside the vaginal canal. 432 
 433 
3.5 In vitro release experiments 434 
Release studies through porcine epithelial mucosa obtained from vaginal tissue were 435 
performed on Franz diffusion cells with four different systems in the donor compartment: 436 
PGT solution, ICs solution, CHT gel+IC and Crinone
®
. The accumulated PGT (%) as a 437 
function of time (h) was plotted (Fig. 8). The permeation rate of the PGT in solution was 438 
much greater than the rate of the other systems (A).  439 
For PGT solution, 49 % and 100 % of the initial amount of PGT permeated at 24 h and 60 440 
h, respectively. For ICs solution, at 24 h, 15 % of the drug was accumulated in the receptor 441 
compartment and at the end of the assay (170 h) it reached 89 % of PGT. The profiles of 442 
PGT and ICs solutions were compared according to a model independent approach utilizing 443 
a difference factor (f1) and a similarity factor (f2) using Equation 6 and 7, respectively. The 444 
profiles were found to be different because f1 was greater than 15 and f2 less than 50 (f1 = 445 
59.6 and f2 = 19.9). It was reported that hydrated CD molecules and ICs are able to 446 
penetrate into the lipophilic biological barriers with considerable difficulty (Loftsson and 447 
Masson, 2001). At the surface of the biological membrane, the drug is released from the IC; 448 
therefore, the CD + Drug ↔ IC equilibrium moves to the left as the drug penetrates the 449 
membranes (Stella et al., 1999; Shimpi et al., 2005). The partition of the drug from the 450 
cavity into the lipophilic barrier could explain the delay in the PGT permeation from ICs 451 
solution, with respect to the PGT solution. This result agrees with the consideration that ICs 452 
can retard the release of guest molecules, which is a suitable alternative for controlling 453 
release. 454 
The amount of PGT permeated from the gels increased slowly along time in a sustained 455 
manner (B). However, the diffusion rate from the commercial gel was slightly higher. At 24 456 
h, 8 % and 5 % of PGT was accumulated from Crinone
®
 and CHT gel+IC, respectively. At 457 
the end of the assay, the percentages were 33 % and 29 % for Crinone
®
 and CHT gel+IC, 458 
respectively.  f1 and f2 values were 12.0 and 69.5, and indicated equivalence between both 459 
gels profiles. In addition, the gels presented a diffusion rate lower than the PGT and ICs 460 
solutions, as a result of the presence of the polymeric matrix. There is not only an increase 461 
in the pathway that the drug has to migrate to reach the surface of the epithelial mucosa but 462 
also two partition equilibriums. In the case of CHT gel+IC, a partition from the CD cavity 463 
to the gel and then from the gel to the epithelium. For Crinone
®
, the first step involves the 464 
dissolution of crystals, and then PGT is partitioned into the gel and diffuses to reach the 465 
epithelium.   466 
It is noteworthy, that a CHT solution containing complexes between PGT and RAMEβ-CD 467 
can form a gel in situ, which presents a similar release profile than a commercial 468 
formulation. The ICs were well incorporated in the GP solution generating a clear mixture. 469 
In the commercial gel the direct incorporation of the hydrophobic hormone leads to the 470 
formation of drug crystals (Fig. 6 C) even with the presence of oil components in the 471 
formulation. Therefore, the CHT gel+IC shown to be superior in respect to the simplicity of 472 
preparation. The ability of CHT to interact with mucus indicates that the residence time of 473 
the CHT gel+IC at the vaginal site would be enough to provide localized sustained release 474 
of PGT. In addition, vaginal insert based on CHT showed better mucoadhesion than inserts 475 
based on carbopol which is one of the main components of Crinone
®
 (Darwesh et al., 476 
2018). Vaginal irritation and other undesirable effects at the site of application were 477 
reported for Crinone
®
. These effects would be less significant with the CHT gel+IC due to 478 
the formulation has fewer inactive ingredients and the biocompatibility of the polymer was 479 
showed in vaginal formulations based on the lack of toxicity and absence of inflammatory 480 
reactions (Tuğcu-Demiröz et al., 2013; Darwesh et al., 2018; Cook and Brown, 2018). 481 
Crinone
®
 is applied as a gel, while the low viscosity of the thermosensitive CHT 482 
formulation ensures the capacity of covering the required surface of the tissue resulting in 483 
the in situ formation of a gel mucoadhesive layer at the physiological temperature.   484 
 485 
4. Conclusions 486 
Inclusion complexes of progesterone and randomly methylated β-cyclodextrin were 487 
obtained by the freeze-drying method. These complexes were included into the 488 
glycerophosphate solution during the preparation of chitosan thermosensitive hydrogels. 489 
The chitosan gel with inclusion complexes and Crinone
®
,
 
which is a vaginal gel used to 490 
supplement progesterone in women who have luteal phase defect, were tested in vitro in a 491 
diffusion assay. This experiment was carried out to evaluate the delivery of the hormone 492 
and its diffusion through porcine epithelial mucosa obtained from vaginal tissue. Chitosan 493 
gel presented sustained diffusion similar to the exhibited by commercial gel. The use of 494 
chitosan gels containing inclusion complexes prepared with progesterone and randomly 495 
methylated β-cyclodextrin is proposed as a viable alternative for vaginal hormone delivery. 496 
The use of a natural polymer as chitosan and a pharmaceutical ingredient as cyclodextrins 497 
could help to avoid side effects associated with the commercial gel.  498 
 499 
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Figure captions 701 
Figure 1. Phase solubility diagrams of PGT A) with β-CD in water and B) with RAMEβ-702 
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Figure 2. Thermal transitions of PGT (red), RAMEβ-CD (yellow), 1 1 PGT/RAMEβ CD 704 
physical mixture (blue) and 1 1 PGT/RAMEβ-CD IC (green). 705 
Figure 3. Proton nuclear magnetic resonance spectra of PGT (red) and the IC (green). 706 
Figure 4. Electron micrographs of A) PGT (4000x), B) RAMEβ-CD (2000x), C) 1:1 707 
PGT/RAMEβ-CD physical mixture (2000x) and D) 1 1 PGT/RAMEβ-CD IC (1000x). 708 
Figure 5. Infrared spectra of PGT (red), Crinone
®
 (blue), CHT gel+IC (light green), IC 709 
(green), and CHT gel (grey). 710 
Figure 6. Electron micrographs of A) CHT gel (400x), B) CHT gel+IC (400x) and C) 711 
Crinone
®
 (800x), scale 20 μm. 712 
Figure 7.  Frequency dependence of the storage (G´) and loss moduli (G´´) for CHT gel+IC 713 
(A) and Crinone
®
 (B). Curves of complex viscosity as function of frequency for CHT 714 
gel+IC (C) and Crinone
®
 (D). 715 
Figure 8. Percentage of accumulated PGT (%) as a function of time (t) for PGT solution, IC 716 
solution, Crinone
®
 and CHT gel+IC. 717 
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Table 1. Solubility (So), Apparent Stability Constants (K1:1) and Complexation Efficiencies 
(CE) values. 
 
CD 
Solvent (v:v) 
 So (mM) K1:1 (M
-1
) CE 
water EtOH 
β-CD 100 - 0.0106±0.0001 46256.79±3614.41  0.489±0.035a 
RAMEβ-CD 
100 - 0.0058±0.0041 74526.09±3326.72  0.433±0.004
a
 
50 50 13.36±2.24 27.13±8.16 0.362±0.036
b
 
a,b
 Different superscript letters in a column indicate statistically significant differences 
between groups (analysis of variance and Fisher test, p < 0.05) 
 
Table
Table 2. Inclusion Efficacy (E%) and Inclusion Yield (Y%) for PGT/RAMEβ-CD inclusion 
complexes. 
 
COMPLEX 
PGT:RAMEβ-CD  
(mol:mol) 
E (%) Y (%) 
IC1 1:1 95.23±4.22
a
 47.95±7.72
b
 
IC2 1:5 98.25±2.74
a
 82.12±11.04
a
 
IC3 1:10 99.56±0.76
a
 77.50±19.64
a
 
IC4 1:20 86.74±2.57
b
 91.33±12.80
a
 
a,b
 Different superscript letters in a column indicate statistically significant differences 
between groups (analysis of variance and Fisher test, p < 0.05) 
 
Table
Table 3. Chemical shift values (δ) of protons of the free and included PGT and values of 
the chemical shift differences (Δδ). 
 
PGT 
Proton δFree(ppm) δIC(ppm) Δδ(ppm) 
H (4) 5.721 5.734 0.013 
CH3 (18) 0.655 0.664 0.009 
CH3 (19) 1.175 1.182 0.007 
CH3 (21) 2.112 2.121 0.009 
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